Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension

Published:2020-12 Issue:12 Volume:10 Page:2339-2347
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Yang Yuncong,Zhang Sirui,Zhou Qian,Zhang Chen,Gao Yuqi,Wang Hao,Li Zhe,Wu Deyan,Wu Yinuo,Huang Yi-You,Guo Lei,Luo Hai-Bin

Funder

National Natural Science Foundation of China

Science Foundation of Guangzhou City

Fundamental Research Funds for the Central Universities

China Postdoctoral Science Foundation

Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference28 articles.

1. Models and molecular mechanisms of world health organization group 2 to 4 pulmonary hypertension;Xiong;Hypertension,2018

2. Advances in therapeutic interventions for patients with pulmonary arterial hypertension;Humbert;Circulation,2014

3. An evaluation of long-term sur-vival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry;Benza;Chest,2012

4. Survival in patients with idi-opathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era;Humbert;Circulation,2010

5. Management of pulmonary arterial hypertension with a focus on combination therapies;Benza;J Heart Lung Transplant,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBK models to predict internal and external dose levels following oral exposure of rats to imidacloprid and carbendazim;Computational Toxicology;2024-09

2. Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy;Chinese Chemical Letters;2024-05

3. Discovery of novel selective phosphodiesterase‑1 inhibitors for the treatment of acute myelogenous leukemia;Bioorganic Chemistry;2024-03

4. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis;Computers in Biology and Medicine;2024-02

5. Multifunctional nanoparticle-mediated combining therapy for human diseases;Signal Transduction and Targeted Therapy;2024-01-01